New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:54 EDTZGNXZogenix weakness creates buying opportunity, says Oppenheimer
Oppenheimer believes that the recent weakness in Zogenix has been caused by media headlines that rehashed the controversy regarding the approval of its Zohydro drug, as well as a misunderstanding of the company's comments regarding its use of cash. The firm does not expect the FDA to reverse its approval of the drug, and it views the change in the company's Q4 EPS as a result of a non-cash charge as " an accounting artifact." The firm keeps a $5 price target and Outperform rating on the stock.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:21 EDTZGNXZogenix 4.75M share Secondary priced at $18.00
The deal size was increased to 4.75M shares from 3.8M shares. Leerink and Stifel acted as joint book running managers for the offering.
July 28, 2015
19:10 EDTZGNXOn The Fly: After Hours Movers
Subscribe for More Information
16:40 EDTZGNXZogenix files to sell 3.8M shares of common stock
Subscribe for More Information
July 23, 2015
17:15 EDTZGNXIntegrated Core Strategies reports 5.6% passive stake in Zogenix

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use